NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…
ACR Volunteer Leaders Visit Capitol Hill, Lobby for 5 Issues
WASHINGTON, D.C.—Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May as part of the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, rheumatology interprofessional team members, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents….
U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…
Prevent Osteoporotic Fractures with a Fracture Liaison Service
Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…
ACR Leaders to Meet with Members of Congress
On May 16, ACR and ARP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC and Insurance Subcommittee will go to Capitol Hill to advocate on behalf of the College’s membership and our patients. The group represents 31 states and the District of Columbia, and will…
Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…
FDA Approves New Osteoporosis Medication
Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…
Dietary Calcium Intake Not Associated with Bone Loss
Postmenopausal women are often told to consume more than 1,500 mg of calcium daily to reach neutral bone balance. But new research suggests this recommendation should be revised, finding no connection between dietary calcium intake and postmenopausal bone loss…
FDA Greenlights Osteoporosis Drug for Postmenopausal Women
(Reuters)—The U.S. Food and Drug Administration says it has approved Amgen’s osteoporosis treatment for postmenopausal women who are at high risk of fracture. Evenity (romosozumab-aqqg), developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Romosozumab-aqqg belongs to a new…
Tracking Bone Deterioration in Patients with Ankylosing Spondylitis
Trabecular bone score and high-resolution peripheral quantitative computed tomography may be effective for evaluating bone impairment in patients ankylosing spondylitis (AS). Rheumatologists may be able to use these methods, complementary to dual-energy X-ray absorptiometry, to identify bone quality deterioration in AS patients.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 19
- Next Page »